Lowering the dose after weight loss: what the SURMOUNT-MAINTAIN trial shows
The first large trial on lowering the dose after weight loss: what happens on the full dose, on 5 mg and after stopping treatment.

What happens after you've lost weight on Mounjaro? Do you have to stay on the same dose for life, can you lower it, or can you stop treatment? Until recently there were no direct data. In May 2026, The Lancet published SURMOUNT-MAINTAIN, the first large trial to test exactly this: lowering the dose after weight loss.
In short: after 60 weeks on the maximum tolerated dose of tirzepatide, patients who continued the same dose ended at −21.9% from their starting weight, those switched to 5 mg at −16.6%, and those switched to placebo at −9.9%. The reduced dose preserved a large part of the result, but less than the full dose. The authors describe it as a valuable alternative to stopping treatment, not as an equivalent.
Why this trial matters
We already know that stopping treatment leads, on average, to regaining a large part of the weight. For example, in the STEP 1 extension, participants regained about two-thirds of the weight they had lost in the year after stopping semaglutide.
Between "continue the full dose" and "stop", however, there were no data on a middle path. Many patients and doctors lower the dose for practical reasons (side effects, cost) without knowing what result to expect. SURMOUNT-MAINTAIN measured exactly that.
How the trial was done
- Participants: 441 adults in the US with obesity, or overweight with at least one complication, who had previously tried to lose weight through diet without success. Average starting weight: 113.8 kg.
- Phase 1 (60 weeks): everyone received tirzepatide at the maximum tolerated dose (10 or 15 mg).
- Phase 2 (52 weeks): 378 participants were randomly assigned to three groups:
- continued the maximum tolerated dose;
- lowered to 5 mg;
- switched to placebo.
- The trial was double-blind in phase 2: neither patients nor doctors knew who was receiving what.
- If someone regained more than half of the weight they had lost, they could receive tirzepatide again ("rescue treatment"), starting at week 84.
- 91% of participants completed the trial.
The results
Weight at the end of the trial (week 112), compared with the start of treatment:
| Group | Loss from starting weight |
|---|---|
| Continued the maximum tolerated dose | −21.9% |
| Lowered to 5 mg | −16.6% |
| Switched to placebo | −9.9% |
How many regained at least half of the weight they had lost:
| Group | Share |
|---|---|
| Maximum tolerated dose | 8% |
| 5 mg | 25% |
| Placebo | 67% |
Improvements in waist size, blood sugar, blood pressure and cholesterol were maintained on both tirzepatide doses compared with placebo. Side effects were mainly gastrointestinal, mild or moderate, and occurred mostly during dose escalation.
How to interpret the results
1. The reduced dose works, but not as well. The result ties in with what the SURMOUNT-1 trial had already shown for 5 mg. Patients switched to 5 mg kept much more than those who stopped treatment, but less than those who continued the full dose.
2. The risk of regaining weight goes up. One in four patients on 5 mg regained at least half of the weight they had lost. On the full dose, one in 12.5.
3. Stopping treatment remains the riskiest option. Two-thirds of those switched to placebo regained at least half of the weight in less than a year.
4. The response is individual. The authors stress that the response to a reduced dose varies from patient to patient. Lowering the dose requires follow-up, so you can see how your body responds.
The trial's limitations
- It was funded by the manufacturer (Eli Lilly), like most large trials with these medicines.
- It included only participants in the US, mostly women (65%).
- The maintenance phase lasted one year. We don't know what happens after several years on a reduced dose.
- It tested only switching to tirzepatide 5 mg. The results don't automatically apply to semaglutide (Wegovy, Ozempic) or to other doses.
What it means for patients
If you've lost weight on Mounjaro and are thinking about a lower dose, this trial gives you a concrete basis for the conversation with your doctor:
- lowering to 5 mg is a studied option, better than stopping;
- you will probably keep a smaller part of the result than on the full dose;
- you need regular weigh-ins and a plan in case your weight starts to rise;
- diet and physical activity remain important in the maintenance phase;
- the benefits for blood pressure, blood sugar and cholesterol matter too, not just the pounds (see GLP-1 and the heart/kidneys).
Don't lower the dose on your own. More on how to approach the conversation in the guide to talking with your doctor.
If you lower your dose with your doctor, a Mounjaro tracker app such as Reko (partner app, iPhone) shows your weight next to each dose, so any regain is visible early.
Frequently asked questions
Can I lower my Mounjaro dose after losing weight? The SURMOUNT-MAINTAIN trial shows that lowering to 5 mg can preserve a large part of the result, more than stopping treatment. The decision is made only with your doctor.
How much weight did patients who lowered the dose regain? On average, they ended at −16.6% from their starting weight, versus −21.9% for those who continued the full dose. 25% regained at least half of the weight they had lost.
What happens if I stop completely? In the trial, 67% of those switched to placebo regained at least half of the weight they had lost in less than a year.
Does this also apply to Wegovy or Ozempic? Not directly. The trial tested only tirzepatide (Mounjaro). There is not yet a similar dose-reduction trial for semaglutide.
Was the trial funded by the manufacturer? Yes, by Eli Lilly. However, it was published in a peer-reviewed journal (The Lancet), with a publicly registered protocol (NCT06047548).
Useful calculators
- Mounjaro calculator: the approved doses and results for each dose, useful if you're discussing a switch to 5 mg with your doctor.
- BMI calculator: track your body mass index during the maintenance phase.
The "GLP-1 dose" series
- The minimum effective GLP-1 dose: do you need the maximum dose?
- Mounjaro 5 mg vs 10 mg vs 15 mg: what the trials show
- Lowering the dose after weight loss: the SURMOUNT-MAINTAIN trial
- GLP-1 microdosing: what's real and what's marketing
- Ozempic overdose: why you shouldn't calculate your own dose
- Reducing your GLP-1 dose: how to talk to your doctor
Sources
- Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026;407:2305-2318. doi:10.1016/S0140-6736(26)00656-2
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553-1564. doi:10.1111/dom.14725
Educational content, updated September 2026. It does not replace medical advice. Do not change the dose, frequency or way you take a medicine without the agreement of the doctor who prescribed it.
This article is for general information only and does not replace advice from your doctor or pharmacist. Do not start, stop or change a treatment without medical supervision.


